Stay Alert for Lybalvi, a New Combo Antipsychotic

January 1

Rx Lybalvi combines the antipsychotic olanzapine with samidorphan, a new opioid antagonist...for schizophrenia or bipolar disorder.

Samidorphan is derived from naltrexone. But so far, using it alone hasn’t panned out for alcohol use disorder or other conditions.

In Lybalvi, the idea is that samidorphan may lessen weight gain from olanzapine...possibly by blocking opioid receptors that regulate appetite.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Be Ready for Questions About Molnupiravir to Treat COVID-19
Ophthalmology Watch for Vuity, an Eye Drop to Improve Near Vision
Men's Health Compare Meds for Treating Benign Prostatic Hyperplasia
Stroke Think of the “ABCs” to Optimize Meds After a Stroke or TIA
End-of-Life Care Fine-Tune Meds in Hospice or Palliative Care Patients
Supplements Clarify the Role of Turmeric for COVID-19 and Other Uses
E-Cigarettes Explain What FDA Authorization of E-Cigarettes Really Means
Hematology/Oncology Be Familiar With Nuances of Prostate Cancer Meds
Antipsychotics Stay Alert for Lybalvi, a New Combo Antipsychotic
Seizures Evaluate the Need for Seizure Prophylaxis
Antifungals Determine Who May Benefit From Empiric Antifungals